Amgen's Strategic Focus and Growth Outlook for 2026 Explained

Amgen’s key pipeline focus areas (toward long-term growth)

1) Obesity/type 2 diabetes (Meritide) as the central “emerging growth driver”

• Management reiterates that confidence in Meritide continues to build and frames it as a major contributor to future growth. ¹
• The company emphasizes disciplined data generation and execution across important Phase 3 programs—with Meritide specifically called out as an area of focus. ¹
• Meritide is positioned as moving toward less frequent dosing: an additional Phase 3 study will evaluate switching from weekly injectables to every 8 or 12 weeks, and management describes evaluating weight maintenance on a four- or six-injections-per-year schedule. ¹²
• Management’s competitive strategy around Meritide is to compete by targeting a “new paradigm-changing” opportunity in a “massive category,” and to help patients with different starting points (de novo, inadequate response on other therapy, or side-effect/frequency issues). ³

2) Oncology expansion: metastatic hormone-sensitive prostate cancer and bispecific platforms

• Amgen describes advancing into metastatic hormone-sensitive prostate cancer, evaluating zalaritamab on top of standard-of-care hormonal therapy with the goal of a more effective regimen without chemotherapy. ⁴
• The company also highlights its BiTE (bispecific T cell engager) platform and Imdeltra’s impact in cancer care, while working to move Imdeltra into earlier lines of therapy. ⁵
• For rare life-threatening disease treatment continuity and regulatory engagement, management notes the FDA proposed to withdraw Tabneos and that Amgen expects to engage further with the FDA while believing in the benefit-risk profile. ⁵

3) Targeted late-stage investment and portfolio breadth across Phase 3/late-stage

• Management explicitly states that non-GAAP R&D spending increased 16% year over year in the first quarter, reflecting “increased spending on our late stage” including Meritide, Imdeltra (listed as “IMBELTRA”), and opasiran. ⁶
• Beyond Meritide, management points to “strong potential across a number of other programs in late-stage development,” including opazirand and other innovative Phase 3 programs. ²
• The pipeline is also described as having meaningful breadth and depth across four therapeutic areas with a “robust pipeline.” ⁷

4) R&D execution capability upgrade (data/AI) to improve pipeline throughput and regulatory preparation

• Amgen reports tangible enterprise R&D/operations improvements from AI and data science, including reducing manufacturing line clearance time from ~30 minutes to ~2 minutes per batch via AI-enabled automation. ⁸
• In R&D, management claims acceleration in antibody lead optimization by 50%, due to contributions from lead discovery through lead optimization, and it cites improvements in clinical trial enrollment from a proprietary site selection model (reported as significant, “in some cases up to threefold”). ⁴
• Amgen also describes using large language models and agentic AI for regulatory filing preparation, with “early promising results” in ingestion, integration, and document traffic. ⁴
• The company positions these efforts as building measurable R&D and enterprise value, and it references a leadership transition toward AI/data transformation leadership. ⁴²

---

Amgen’s long-term growth strategies for 2026 (as described in the call)

1) 2026 as a “springboard year”: offset legacy declines with emerging growth drivers

• Management frames 2026 as a springboard year for future growth, expecting rapidly growing products to offset the financial impact of patent expirations and increased competition, while next-generation molecules progress through the R&D pipeline. ¹
• The company states it expects emerging growth drivers will more than offset outgoing legacy brands, and it ties this to raising guidance ranges for 2026 revenue and non-GAAP EPS. ⁸
• In operating performance terms, Amgen reports six key growth drivers that generated 70% of sales in the quarter and grew 24% year over year (aggregate). ¹

2) Execution against late-stage pipeline (especially Phase 3) supported by increased investment

• Management reiterates discipline in data generation and execution across Phase 3 programs to drive attractive long-term growth. ¹
• It also connects financial strategy to pipeline spending: non-GAAP R&D spending increased 16% in Q1 to support late-stage assets including Meritide, Imdeltra, and opasiran. ⁶
• The company emphasizes continued scaling and launch readiness for Meritide via manufacturing investment, which functions as a growth enabler once approvals occur. ⁶

3) Manufacturing capacity and scaling for volume growth (including Meritide launch)

• Amgen reports Q1 capital expenditures of $700 million, driven by investments across U.S. manufacturing sites (Ohio, North Carolina, Puerto Rico). ⁶
• It expects capital expenditures of approximately $2.6 billion in 2026, specifically reflecting investments to scale manufacturing capacity for volume growth, including Meritide’s launch. ⁶

4) Investor-return policy (capital to shareholders) alongside reinvestment

• Management reports returning capital through dividends of $2.52 per share, representing a 6% increase compared to 2025. ⁸
• It also states share repurchases not to exceed $3 billion. ⁹

5) Portfolio management: continued rationalization of pipeline and disciplined discontinuations

• Amgen states it discontinued development of AMG 193 (a MTA-cooperative PRMT5 inhibitor) after a comprehensive review. ⁴
• This is presented alongside an emphasis on applying AI and data science to improve drug discovery and therapeutic development outcomes (i.e., reallocating effort toward higher-potential areas). ⁴

---

How the growth plan ties together financially for 2026 (high-level)

• Amgen guides 2026 total revenues to $37.1B–$38.5B and non-GAAP EPS to $21.70–$23.10, explicitly stating these ranges reflect confidence that emerging growth drivers will more than offset outgoing legacy brands. ⁸
• It describes continued profitability expectations, including non-GAAP operating margin of roughly 45% to 46%, while emphasizing continued investment in Meritide’s Phase III program and additional late-stage assets. ⁹

---

Bottom line

Based on the excerpts, Amgen’s 2026 long-term growth emphasis is centered on Meritide (obesity/type 2 diabetes) Phase 3 progression and dosing simplification, complemented by advancing oncology programs (including zalaritamab in metastatic hormone-sensitive prostate cancer, Imdeltra earlier-line expansion, and bispecific platform progress). ¹⁴⁵ In parallel, Amgen’s growth strategy relies on manufacturing scale-up for volume and launches, higher late-stage R&D investment, and using AI/data capabilities to accelerate both clinical and operational execution—while managing the portfolio through disciplined pipeline discontinuations. ⁶⁷⁴